ImpriMed uses artificial intelligence and analysis of live cancer cells to predict personalized drug responses for treating canine lymphoma.

ImpriMed

ImpriMed, founded in 2017 in Silicon Valley, is a leading precision medicine startup revolutionizing cancer treatment with artificial intelligence. The company’s pioneering drug response prediction technology helps reduce costs, accelerate treatment, enhance efficacy, and improve the quality of life for patients. To date, the company’s technology has been deployed across more than 40 U.S. states, and 17,000+ canine and feline blood cancer tests have been performed as of 2024. ImpriMed is now poised to extend its groundbreaking AI-driven approach to human healthcare, redefining the future of oncology treatment with personalized, effective solutions. For additional information, visit www.imprimedicine.com.

Murex Partners

HG Initiative

Draper Associates

Draper Dragon

ES Investor

BonAngels Venture Partners

Primer Sazze Partners

Translink Investment

FuturePlay

Mayo Clinic Platform

Han River Partners

Ignite Innovation Fund

KDB Industrial Bank

Byucksan

SAMYANG CHEMICAL GROUP

SK Telecom

SBVA

Angel Investor

ImpriMed, Inc.

Thank you, TechCrunch, for highlighting our work at ImpriMed! We are on a mission to transform cancer care by empowering clinicians and aiding patients with the best predictive information for personalized treatment.

#petcare #cancercare #personalizedmedicine #precisionmedicine #biotech

🎧 New Episode Alert! 🐾
Tune into the latest episode of the Veterinary Cancer Pioneers Podcast where we're joined by Dr. Heather Wilson-Robles, Chief Medical Officer at Volition Veterinary. Dive into a captivating discussion on the transformative power of mentorship in shaping careers in veterinary oncology. Discover how Dr. Wilson-Robles's journey, from her initial inspiration in pediatric oncology to her leadership role in the industry, highlights the pivotal role of mentor-mentee relationships in professional growth.

#VeterinaryOncology #Mentorship #VeterinaryMedicine #ProfessionalGrowth #Podcast #VeterinaryCancerPioneers #Leadership

Everyone's buzzing about AI (including us)! To boost your AI knowledge, discover how AI is transforming the veterinary field in this AVMA (American Veterinary Medical Association) news article!

P.S. We're thrilled to be mentioned for our role in pioneering AI-driven personalized medicine. It's an exciting time to be part of this AI revolution! 

 #AI #VeterinaryMedicine #Innovation

Step into ImpriMed's Wall of Love! Overflowing with heartfelt support, love, and adorable photos from our amazing veterinarians and pet parents. Dive in and feel the love! 💖🐾: https://lnkd.in/giu2zN8e

#Testimonials #VetSupport #PetParentStories

"I still come across people that are like, 'Wait, dogs, they get cancer?'"
"The veterinary cancer field has done absolutely worlds of work to even get that conversation going. So I'm very proud to have come from that place."

We hear this question a lot as workers in veterinary cancer, and igniting this conversation is exactly what our podcast is all about.

Join our passionate veterinary cancer pioneers, Dr. Rachel Venable, and our new guest, Dr. Nicole Ehrhart, the Director of Colorado State University's Columbine Health Systems Center for Healthy Aging, as we dive into the vast world of veterinary cancer and its comparative aspects.

In this episode, Dr. Ehrhart shares her career journey and delves into the fascinating field of comparative cancer research. She also explores the drivers of aging, the potential of senotherapeutics, and immune regeneration in cancer treatment. Learn how she facilitates interdisciplinary research across various domains to tackle aging challenges and discover the intriguing similarities between the fundamental drivers of cancer and cellular aging.

🎧 https://lnkd.in/grvwdYVz

#veterinarycancer #pethealth #dogcancerawareness
#comparativeresearch #agingresearch #cancertreatment #podcast

Wishing you a great holiday! Celebrate with friends, family, and a good podcast. Catch our latest episode here: https://buff.ly/4cHlMC1

🎙️ The Veterinary Cancer Pioneers Podcast has a brand new episode ready for you!
Join our host, Dr. Rachel Venable, and new guest, Dr. Julius Liptak, the internationally renowned surgical oncologist.

In this episode, they dive into:
🔍 The challenges of cancer surgeries in pets
📍 The crucial role of sentinel lymph node mapping
🔄 The evolving landscape of veterinary oncology
📊 The need for robust data to guide treatments

🔗:https://lnkd.in/gzBPvZmq

#VeterinaryOncology #PetHealth #CancerSurgery

Team ImpriMed—Mitch Buntemeyer, Collin H. Cavanaugh, and Melody Jung—had an amazing experience at the #2024ACVIMForum in Minneapolis, Minnesota! It was wonderful meeting attendees from around the globe and exploring the vibrant city of Minneapolis. We made valuable connections and are already looking forward to seeing everyone in Louisville, KY, for the 2025 Forum! 🌍

#VeterinaryMedicine #TeamImpriMed #Minneapolis #ACVIM #Louisville2025

💖🐾 Featuring the Adorable Kyle Today! 🐾

We received this heartwarming photo from Dr. Sarah Furtney, a Relief Veterinarian at Animology.

“I just wanted to express my gratitude for ImpriMed's help. The work you do is profound, not only does it prolong life for pets, but their humans as well. I'm not sure if you ever get pictures of the pets you are helping, but I'm hoping that Kyle's picture expresses the magnitude of your work.”

Thank you, Dr. Sarah Furtney! We are truly honored. 

#thankyouvets #caninelymphoma #australianshepherd

🧬🐶Our furry friends are crucial allies in the fight against cancer!

Join Dr. Rachel Venable as she dives into conversation with Dr. Amy LeBlanc, a Senior Scientist and Director at the The National Institutes of Health
’s CCR Comparative Oncology Program.

Explore the compelling integration of canine models into cancer research and the translational benefits that dogs offer in understanding and treating human cancers. Dr. LeBlanc also discusses her team’s work with naturally occurring cancers in pets, offering new hope to both humans and animals. 

📹 Tune in for this revolutionary discussion: https://lnkd.in/gu4ZVnZS

#CancerResearch #VeterinaryOncology #PodcastPreview #InnovativeTherapies

msh id	COM:IMPRIMEDICINE
symbol	-
name	ImpriMed
homepage url	https://www.imprimedicine.com
country	US
sector	Healthcare & Health Services
industry	Veterinary Oncology
market	PRIVATE
employee count	-
crunchbase url	-
linkedin url	https://www.linkedin.com/company/imprimed-inc
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

IMPR

COM:IMPRIMEDICINE

ImpriMed

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-